Publication

Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: Results on local control and survival

Bantema-Joppe, E. J., van der Laan, H. P., de Bock, G. H., Wijsman, R., Dolsma, W. V., Busz, D. M., Langendijk, J. A. & Maduro, J. H., Aug-2011, In : Radiotherapy and Oncology. 100, 2, p. 215-220 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

PURPOSE: To report on local control and survival after breast conserving therapy (BCT) including three-dimensional conformal simultaneous integrated boost irradiation (3D-CRT-SIB) and on the influence of age on outcome.

PATIENT AND METHODS: For this study, 752 consecutive female breast cancer patients (stages I-III), treated with 3D-CRT-SIB at the University Medical Center Groningen from 2005 to 2008, were retrospectively identified. Median age was 58.4 (range 26-84) years. The SIB fractionation used was: 28×1.8Gy (whole breast) and 28×2.3Gy or 2.4Gy (tumour bed). Next to outcome, we estimated the effect of age on the recurrence-free period (RFP) by multivariate Cox regression survival analysis.

RESULTS: Median follow-up was 41 (range 3-65) months. Local control was 99.6% at 3 years (6 ipsilateral recurrences). The 3-year locoregional control, RFP and overall survival (OS) rates were 99.2%, 95.5%, and 97.1%, respectively. In multivariate analysis, tumours >2cm (hazard ratio (HR) 3.11; 95% confidence interval (CI) 1.57-6.17) and triple negativity (HR 3.03; 95% CI 1.37-6.67) and not age were associated with impaired RFP.

CONCLUSIONS: At 3 years, the 3D-CRT-SIB technique in BCT results in excellent local control and OS. Age was not a risk factor for any recurrence.

Original languageEnglish
Pages (from-to)215-220
Number of pages6
JournalRadiotherapy and Oncology
Volume100
Issue number2
Publication statusPublished - Aug-2011

    Keywords

  • Breast conserving therapy, Radiotherapy, Simultaneous integrated boost, Local control, Young, RANDOMIZED-TRIALS, PROGESTERONE-RECEPTOR, INTENSITY MODULATION, DISTANT RECURRENCE, ESTROGEN-RECEPTOR, 15-YEAR SURVIVAL, YOUNG-WOMEN, FOLLOW-UP, CANCER, RADIOTHERAPY

ID: 5403597